RESUMO
Background: As the 2019 coronavirus spreads rapidly around the world, it has caused widespread fear and anxiety in various populations. This study aimed to explore the psychological effects of COVID-19 on patients with this disease. Materials and Methods: A qualitative study was conducted with a phenomenological approach. A purposive sample of 11 patients with COVID-19 was recruited. Data were collected from the beginning of March to the beginning of June 2020 using semi-structured interviews and they were analyzed according to Van Manen's method. Interviews were audiotaped, transcribed verbatim, and analyzed using thematic analysis. Results: Initially, 315 codes were extracted. During data analysis and comparisons, the codes were reduced to 108. Ultimately, 10 categories, 38 subcategories, and 3 themes emerged. The theme of "behavioral responses" including 5 categories (Remorse, Fear and despair, Death anxiety, Growth, Support), "disease-caused helplessness" including two categories (Failure, Denial), and "decline of social networks" including three categories (Rejection, Stigma, Feeling guilty). Conclusions: After understanding the findings of this research, nurses working in the wards of patients with COVID-19 can better consider the importance of assessing and analyzing the psychological challenges and experiences of these patients during the course of illness and quarantine. Findings also enhance the identification and organization of training needs during such a pandemic and the design of nursing programs to meet them.
RESUMO
BACKGROUND: Fear of hypoglycemia is a medical emergency which leads to disrupt individuals' normal lives. Peers support is a hopeful approach to improve diabetes self-care behaviors. This study was conducted to assess the effect of peers support on the fear of hypoglycemia in patients with type 1 diabetes. MATERIALS AND METHODS: This randomized clinical trial study was performed among 60 patients with type 1 diabetes in Qazvin city from September 2019 to October 2020. Patients were assigned to control and intervention groups using a random method. The data collection tools included demographic characteristics and a standard questionnaire for Hypoglycemia Fear Survey (HFS). Patients in the intervention group were trained by skilled peers for 2 months, but those of the control group only received routine hospital training. The data were analyzed by SPSS version 16 and paired and independent t-test. RESULTS: The scores of the fear of hypoglycemia in diabetic patients in the two groups had no significant statistical difference before intervention (t53 = 0.93, p = 0.94). But after the intervention, the independent t-test showed that there was a significant difference between the scores of the fear of hypoglycemia in both groups (t53 = -2.13, p = 0.03). CONCLUSIONS: Considering the results of the current study, peer support for diabetic patients is an effective way to reduce the fear of hypoglycemia. Therefore, it is recommended using this training method to train diabetic patients.
RESUMO
In patients on maintenance hemodialysis several factors reduce the body stored carnitine which could lead to dyslipidemia, anemia, and general health in these patients. We evaluated the effect of oral L-carnitine supplementation on lipid profiles, anemia, and quality of life (QOL) in hemodialysis patients. In a randomized, double-blinded, placebo-controlled trial, end-stage renal disease (ESRD) patients on hemodialysis received either L-carnitine 1 g/d (n = 24) or placebo (27 patients) for 16 weeks. At the end of the study, there was a significant decrease in triglyceride (-31.1 ± 38.7 mg/dL, P = 0.001) and a significant increase in HDL (3.7 ± 2.8 mg/dL, P < 0.001) levels in the carnitine group. Decrease in total cholesterol (-6.6 ± 16.0 mg/dL, P = 0.075) and increase in hemoglobin (0.7 ± 1.7 g/dL, P = 0.081) concentrations in the carnitine group were not significant. There was no statistically significant changes in LDL in any group (P > 0.05). Erythropoietin dose was significantly decreased in both the carnitine (-4750 ± 5772 mg, P = 0.001) and the placebo group (-2000 ± 4296 mg, P < 0.05). No improvement was observed in QOL scores of two groups. In ESRD patients under maintenance hemodialysis, oral L-carnitine supplementation may reduce triglyceride and cholesterol and increase HDL and hemoglobin and subsequently reduce needed erythropoietin dose without effect on QOL.
